Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine

Leukemia

Volumn 11, Issue 6, 1997, Pages 788-791

  Cortes, J ^a   Kantarjian, H ^a   Talpaz, M ^a   O'Brien, S ^a   Beran, M ^a   Koller, C ^a   Keating, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myeloid leukemia; Deoxycoformycin; Fludarabine

Indexed keywords

ALPHA INTERFERON; FLUDARABINE; NUCLEOSIDE ANALOG; PENTOSTATIN;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; HUMAN; NAUSEA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

EID: 0030914423     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400677     Document Type: Article

References (22)

1. Cheson BD. Purine analogs in lymphoproliferative disorders. Leuk Lymphoma 1993; 11 (Suppl. 2): 153-159.
2. Chun HG, Leyland JB, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lyniphoid malignancies. J. Clin Oncol 1991; 9: 175-188.
3. Saven A, Piro LD. 2-chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies. Leuk Lymphoma 1993; 10 (Suppl.): 43-49.
4. Warrell RP Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4: 74-79.
5. Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 1986; 46: 5953-5958.
6. Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous toxicity of fludarabine phosphate. Cancer Treat Rep 1986; 70: 1225-1228.
7. Santana VM, Mirro J Jr, Kerans C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemias. J Clin Oncol 1992; 10: 364-370.
8. Santana VM, Hurwitz CA, Blakley RL, Crom WR, Luo X, Roberts WM, Ribeiro R, Mahmoud H, Krance RA. Complete hematologie remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84: 1237-1242.
9. Vahdat L, Warrell RP Jr. Treatment of acute myeloblastic leukemia in adults with 2-chlorodeoxyadenosine. Blood 1993; 82 (Suppl. 1): 129a.
10. Kornblau S, Andreeff M, Beran M, Escudier S, Kantarjian H, Koller C, O'Brien S, Robertson LE, Estey E. 2-CdA ± ara-C is ineffective therapy for relapsed or refractory AML in adults. Proc Am Soc Clin Oncol 1995; 14: 336 (Abstr. 1005).
11. Konwalinka G, Helson C, Braverman S, Petzer G, Bilgeri R, Zihan U. Growth inhibitory properties of 2-chlorodeoxyadenosine (2CdA) against human nervous system tumors. In: Abraham NG, Knwalinka G, Marks P (eds). Molecular Biology of Hematopoiesis. Intercept Ltd: Andover, MA, 1992, pp 603-613.
12. Zinzani PL, Buzzi M, Farabegoli P, Martinelli G, Tosi P, Zuffa E, Visani G, Testoni N, Salvucci M, Bendandi M, Zaccari A, Tura S. Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells. Haematologica 1994; 79: 127-131.
13. Saven A, Piro LD, Lemon RH, Figueroa ML, Kosty M, Ellison DJ, Beutler E. Complete hematologie remissions in chronic phase, Philadelphia chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 1994; 73: 2953-2963.
14. Marks RS, Letendre L, Reid JM, Bagniewski PC, Ames MM. A phase I and pharmacologic study of chlorodeoxyadenosine in patients with chronic myelomonocytic or chronic granulocytic leukemias. Proc Am Soc Clin Oncol 1994; 13: 155 (Abstr. 415).
15. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-1446.
16. Kantarjian HM, Smith TL, O'Brien S, Beran M, Robertson LE, Koller C, Pierce S, Keating M, Talpas M. Prolonged survival following achievement of cytogenetic response with alpha Interferon therapy in chronic myelogenous leukemia. Ann Intern Med 1995; 122: 254-261.
17. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Quieβer W, Löffler H, Heinze B, Georgii A, Wussow PV, Bartram C, Grieβhammer M, Bergmann L, Essers U, Falge C, Hochhaus A, Queiβer U, Sick C, Meyer P, Schmitz N, Verpoort K, Eimermacher H, Walther F, Westerhausen M, Kleeberg UR, Heilein A, Käbisch A, Barz C, Zimmerman R, Meuret G, Tichelli A, Berdel WE, Kanz L, Anger B, Tigges FJ, Schmid L, Brockhauss W, Zankovich R, Schläfer U, Weiβenfels l, Mainzer K, Tobler A, Perker M, Hohnloser J, Messenger D, Thiele J, Buhr T, Ansari H and the German CML Study Group. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 1993; 83: 398-407.
18. Robak T, Korycka A, Gora-Tybor J. The interaction of 2-chlorodeoxyadenosine (2-CDA) and interferon α(IFN-α) on normal and myeloid leukemia hematopoiesis in vitro. Leukemia Res 1994; 18: 275-281.
19. O'Dwyer PJ, Spiers ASD, Marsoni S. Association of severe and fatal infections and treatment with pentostatin. Cancer Treat Rep 1986; 70: 1117-1120.
20. Anaissie E, Kontoyiannis DP, Kantarjian H, Etling L. Listeriosis in patients treated with fludarabine and prednisone. Ann Intern Med 1992; 117: 466-469.
21. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. I Clin Oncol 1995; 13: 2431-2448.
22. Barrett A, Jiang YZ. Immune responses to chronic myeloid leukemia. Bone Marrow Transplant 1992; 9: 305-311.